Pfizer to open global network of digital hubs, including in Greece

Pfizer sign
Pfizer expects the Greek facility, the first of six, to become operational in 2020, providing up to 200 jobs. (Tracy Staton)

Pfizer is planning to establish a multinational network of digital research hubs with a focus on artificial intelligence and big data analytics.

Starting with a new facility in the Greek city of Thessaloniki, the Big Pharma hopes to develop tech that can be incorporated into its development pipeline of medicines and vaccines.

“There is a high concentration of digital talent in Greece,” a company spokesperson told FierceMedTech. “Pfizer plans to partner with universities and local innovation incubators to assemble a world-class team in Thessaloniki—one that will help us further advance our purpose: breakthroughs that change patients’ lives.”


CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

Pfizer expects the facility, the first of six, to become operational in 2020, providing up to 200 jobs. The company has not finalized plans for the remaining locations.

RELATED: Pfizer hires ex-FDA, MD Anderson researcher as clinical oncology lead

The news was first reported by the Athens newspaper Kathimerini, which said Greek Prime Minister Kyriakos Mitsotakis announced the city’s selection during the Thessaloniki International Fair.

Pfizer currently maintains a separate network of "Healthcare Hubs" in different locations across the globe—including New York, London, Berlin, Tel Aviv, Stockholm, Sydney and Toronto—that focus on supporting healthcare and tech startups through the company’s local subsidiaries, plus institutional resources and grants.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.